Continuing basic research based on comprehensive cancer gene analysis
First written in FY2016. 18 of 22 entries say "Restated". Latest entry: 2026-07-10.
No other company in this theme has enough history to compare yet.
- 2026-07-10AdvancedOther Disclosures
「CPM Co. is responsible for whole-genome cancer analysis, transcriptome analysis and other activities in a research project based on the Ministry of Health, Labour and Welfare's "Whole Genome Analysis, etc. Implementation Plan." In this presentation, CPM Co. will explain the current state of quality control in whole-genome analysis and the issues involved in its implementation in society.」
It was stated that CPM Co. is responsible for a research project based on the Whole Genome Analysis, etc. Implementation Plan and will present at an academic conference on quality control in whole-genome analysis and issues relating to its implementation in society. - FY2026AdvancedAnnual report
「In addition, CPM has newly introduced analytical technologies including whole-genome sequencing using long-read sequencing. Furthermore, CPM has entered into a joint research agreement with the Human Genome Center at the Institute of Medical Science, The University of Tokyo, to develop genome data analysis technologies that rapidly process the vast amounts of data obtained through long-read sequencing and other methods and organize the necessary information, with the aim of further promoting genome research and genomic medicine.」
Regarding the genome research and analysis platform, CPM has newly introduced long-read sequencing technology and has advanced the development of genome data analysis technologies through joint research with the Human Genome Center at the Institute of Medical Science, The University of Tokyo. - FY2026-H1AdvancedAnnual report
「In addition, CPM has entered into a joint research agreement with Showa University and Nonacus to establish genetic testing for brain tumors, as well as a joint research agreement with the Human Genome Center at the Institute of Medical Science, The University of Tokyo, as announced on 17 October 2025, to promote genome research and genomic medicine.」
A new joint research agreement with the Human Genome Center at the Institute of Medical Science, The University of Tokyo, has been specified as part of the research platform for comprehensive genome analysis and genomic medicine. - FY2025RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently President of the National Institutes of Biomedical Innovation, Health and Nutrition, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2023-Q3RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently President of the National Institutes of Biomedical Innovation, Health and Nutrition, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development (Note 1). We are also actively pursuing drug discovery research in each of these fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs, targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2023-Q1RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently President of the National Institutes of Biomedical Innovation, Health and Nutrition, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2022-Q3RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development (Note 1). We are also actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2022-Q1RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2021-Q3RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene analysis and identification of target molecules. - FY2021-Q2RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2021-Q1RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2020-Q3RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2020-Q2RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene analysis and identification of target molecules. - FY2020-Q1RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with Professor Nakamura Yusuke (中村祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently Director of the Cancer Precision Medicine Research Center at the Cancer Institute of the Japanese Foundation for Cancer Research, Professor Emeritus at The University of Tokyo and Professor Emeritus at the University of Chicago, and identified many target molecules suitable for cancer drug development. We are currently actively pursuing drug discovery research targeting these molecules」
Drug discovery research targeting these molecules continues, based on past comprehensive gene expression analysis and identification of target molecules. - FY2018RestatedAnnual report
「From 2001 to 2013, our group conducted comprehensive gene expression analyses and other studies covering almost all cancers through joint research with the Institute of Medical Science, The University of Tokyo, and identified many target molecules suitable for cancer drug development.」
Comprehensive gene analysis and identification of target molecules based on joint research with The University of Tokyo are reaffirmed as an ongoing research platform. - FY2018-Q3RestatedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, our Group has conducted comprehensive gene-expression analyses covering nearly all cancers and has already identified many target molecules suitable for cancer drug development.」
Comprehensive gene-expression analysis covering nearly all cancers and identification of target molecules continue. - FY2018-Q2RestatedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, our Group has conducted comprehensive gene-expression analyses covering nearly all cancers and has already identified many target molecules suitable for cancer drug development.」
Comprehensive gene-expression analysis covering nearly all cancers and identification of target molecules continue. - FY2017RestatedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, we have conducted comprehensive gene-expression analyses covering nearly all cancers and have already identified many target molecules suitable for cancer drug development.」
Comprehensive gene-expression analysis and target-molecule identification continue as the foundation of the research framework, including collaboration with the University of Chicago. - FY2017-Q3RestatedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, our Group has conducted comprehensive gene-expression analyses covering nearly all cancers and has already identified many target molecules suitable for cancer drug development.」
Comprehensive gene-expression analysis covering nearly all cancers and identification of target molecules continue. - FY2017-Q2RestatedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, our Group has conducted comprehensive gene-expression analyses covering nearly all cancers and has already identified many target molecules suitable for cancer drug development.」
Comprehensive gene-expression analysis and target-molecule identification continue. - FY2017-Q1RestatedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, our Group has conducted comprehensive gene-expression analyses covering nearly all cancers and has already identified many target molecules suitable for cancer drug development.」
Basic research and identification of target molecules continue. - FY2016First statedAnnual report
「In collaboration with Professor Yusuke Nakamura (中村 祐輔), former Director of the Human Genome Center at the Institute of Medical Science, The University of Tokyo and currently a professor at the University of Chicago, our Group has conducted comprehensive gene-expression analyses covering nearly all cancers and has already identified many target molecules suitable for cancer drug development.」
Describes an analytical platform covering 32,000 types of cDNA using cDNA microarrays, the LMM method and other technologies.